The overall program is designed to provide an update on regulatory expectations from a truly global perspective with representatives from the EU, the US, and Asia presenting the scientific framework for virus safety of plasma-derived and biotechnology medicinal products, as well as particularly innovative advanced therapy medicinal products. Following on from the recent publication of the draft ICH Q5A R2 document, one of the conference's main themes will be best practices and understanding of the recommendations in this draft document.

Click here for more information and to register